Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China.
M2 PHARMA-May 10, 2019-Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China
(C)2019 M2 COMMUNICATIONS
- Chinese biotechnology company Clover Biopharmaceuticals has received Clinical Trial Application approval from the Chinese National Medical Products Administration to conduct clinical trials in China with SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, for the treatment of cancer patients with intracavitary malignancies, the company said.
A phase I clinical trial for malignant ascites is planned to initiate in China this year.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercialising biologic therapies, with a focus on oncology and autoimmune diseases.
Clover is utilizing its proprietary Trimer-Tag(c) technology platform to develop novel biologics targeting trimerization-dependent pathways.
Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
Trimer-Tag(c) is a drug development platform which allows the production of novel, covalently-trimerized fusion proteins.
Many major disease targets are trimerization-dependent such as the tumor necrosis factor superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells.
Clover is using Trimer-Tag(c) technology to create trimerized fusion proteins that are able to effectively target these previously undruggable pathways.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||May 10, 2019|
|Previous Article:||Mati Therapeutics Phase II Nepafenac Evolute Clinical Trial Results Show Significant Post-Operative Pain Reduction in Cataract Surgery Patients.|
|Next Article:||European Commission Approves Lorviqua for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer.|